Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.47 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11059385 | 1.00 | MAOA (0.54) | MAOAMAOBKCNH2RIOK2KDM4E | |
| SCHEMBL20658872 | 0.77 | MAOA (0.56) | MAOAMAOBKCNH2RIOK2KDM4E | |
| SCHEMBL20658871 | 0.77 | MAOA (0.56) | MAOAMAOBKCNH2RIOK2KDM4E | |
| SCHEMBL20865430 | 0.74 | MAOA (0.71) | MAOAMAOBKCNH2KDM4EALDH1A1 | |
| SCHEMBL3499053 | 0.71 | MAOA (0.50) | MAOAMAOBKCNH2ALDH1A1 | |
| SCHEMBL3499052 | 0.71 | MAOA (0.50) | MAOAMAOBKCNH2ALDH1A1 | |
| SCHEMBL11883699 | 0.71 | NPC1 (0.49) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11883704 | 0.71 | NPC1 (0.49) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL407010 | 0.70 | MAOA (1.00) | MAOAMAOBKCNH2RIOK2ALDH1A1 | |
| SCHEMBL407009 | 0.70 | MAOA (1.00) | MAOAMAOBKCNH2RIOK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108144072-A | For diagnosing the radiopharmaceutical of agglutinin receptor height expression tumour | 北京大学 | 2018-06-12 | — | — | CN | claimed |
| US-9902989-B2 | Methods for the detection of beta-lactamases | BECTON, DICKINSON AND COMPANY (US) | 2018-02-27 | — | — | US | claimed |
| US-20160138076-A1 | Methods And Compositions For The Detection Of Beta-Lactamases | BECTON, DICKINSON AND COMPANY (US) | 2016-05-19 | — | — | US | claimed |
| US-9085794-B2 | Kits for the detection of beta-lactamases | BECTON, DICKINSON AND COMPANY (US) | 2015-07-21 | — | — | US | claimed |
| US-8778303-B2 | 99mTc-labeled 19 amino acid containing peptide for use as phosphatidylethanolamine binding molecular probe and radiopharmaceutical | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20140080164-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF BETA-LACTAMASES | BECTON, DICKINSON AND COMPANY (US) | 2014-03-20 | — | — | US | claimed |
| US-20130058865-A1 | 99mTc-LABELED 19 AMINO ACID CONTAINING PEPTIDE FOR USE AS PHOSPHATIDYLETHANOLAMINE BINDING MOLECULAR PROBE AND RADIOPHARMACEUTICAL | MEDICAL COLLEGE OF WISCONSIN, INC. | 2013-03-07 | — | — | US | claimed |
| US-8389234-B2 | Kits for the detection of beta-lactamases | BECTON, DICKINSON AND COMPANY (US) | 2013-03-05 | — | — | US | claimed |
| US-8097434-B2 | Methods for the detection of beta-lactamases | BECTON, DICKINSON AND COMPANY (US) | 2012-01-17 | — | — | US | claimed |
| CN-119746820-B | Preparation method and application of loofah sponge adsorbent for efficiently recycling gold (III) in electronic waste | 昆明理工大学 | 2025-10-03 | — | — | CN | disclosed |
| US-20250295821-A1 | TARGETED RADIOPHARMACEUTICAL FOR TUMOR AND ITS USE IN THE IMAGING-GUIDED COMBINATION THERAPY OF TARGETED RADIOTHERAPY AND IMMUNOTHERAPY | BeijingGiluntidePharmaceuticalCo.,Ltd. (CN) | 2025-09-25 | — | — | US | disclosed |
| US-12357712-B2 | Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy | BEIJING GILUNTIDE PHARMACEUTICAL CO., LTD. (CN) | 2025-07-15 | — | — | US | disclosed |
| US-12345641-B2 | Fluorescence quenching immunoassay | IDEZZ Laboratories, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-119746820-A | Preparation method and application of loofah sponge adsorbent for efficiently recycling gold (III) in electronic waste | 昆明理工大学 | 2025-04-04 | — | — | CN | disclosed |
| WO-1993003346-A1 | TEST FOR THE RAPID EVALUATION OF ISCHEMIC STATES AND KIT | DIAGNOSTIC MARKERS, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| EP-0312543-A4 | _I(IN SITU) ACTIVE COMPOUND ASSEMBLY | — | 1990-12-27 | — | — | EP | disclosed |
| EP-0312543-A1 | $i(IN SITU) ACTIVE COMPOUND ASSEMBLY | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-04-26 | — | — | EP | disclosed |
| US-4812449-A | SYNTHESIS AT TARGET SITES, MICROENVIRONMENT | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-03-14 | — | — | US | disclosed |
| US-4764462-A | IMMOBILIZED ON SOLID SUPPORT | GEORGETOWN UNIVERSITY (US) | 1988-08-16 | — | — | US | disclosed |
| WO-1988000047-A1 | IN SITU ACTIVE COMPOUND ASSEMBLY | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1988-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130058865-A1 | 99mTc-LABELED 19 AMINO ACID CONTAINING PEPTIDE FOR USE AS PHOSPHATIDYLETHANOLAMINE BINDING MOLECULAR PROBE AND RADIOPHARMACEUTICAL | PHOSPHO1, PEBP1, PTDSS1 | MAOA 4711/4885MAOB 4232/4885KCNH2 3936/4885 |
| US-20250295821-A1 | TARGETED RADIOPHARMACEUTICAL FOR TUMOR AND ITS USE IN THE IMAGING-GUIDED COMBINATION THERAPY OF TARGETED RADIOTHERAPY AND IMMUNOTHERAPY | CD274, ITGB1, ITGA1 | MAOA 4825/4885MAOB 4720/4885KCNH2 3488/4885 |
| US-12345641-B2 | Fluorescence quenching immunoassay | NQO2, FCGRT, MPO | MAOA 438/4885MAOB 363/4885KCNH2 3624/4885 |
| US-12357712-B2 | Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy | CD274, ITGB1, ITGA1 | MAOA 4825/4885MAOB 4720/4885KCNH2 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.